6th Future Healthcare 100 Summit Unveils 'China Story' with 200+ Industry Leaders and 18 Open Forums
Riding the winds of change, every innovator interprets grandeur through small steps. As industries evolve and face fundamental shifts driven by global healthcare development, both the global economy and China’s economic and social development have ushered in new challenges and opportunities. In the healthcare industry, which is closely tied to the well-being of all humanity, the world is witnessing an explosion of innovation from China.
How has China’s healthcare sector responded to the world’s most pressing medical challenges? Amidst a fertile ground for innovation, how is Chinese new drug development demonstrating “China Speed”? With domestically produced medical devices steadily expanding into global markets, the future is already here.
June 14–18, 2022: The 6th Future Healthcare Top 100 Conference will center on the theme “China’s Story,” analyzing industry hotspots from five dimensions—policy orientation, technological frontiers, capital perspectives, industrial innovation, and market demand—to interpret development trends in the future healthcare sector and drive transformative change in innovative healthcare. The conference aims to gather core industry forces, promote transformation in the innovative healthcare sector, and build a comprehensive communication and matchmaking platform for the entire medical and health industry chain.
200+ Key Opinion Leaders
Academicians and IEEE Fellows Lead Nearly 200 Distinguished Experts from Clinical Practice, Academic Research Institutions, Venture Capital, and Industry in Sharing Cutting-Edge Medical Technologies, Industry Trends, and Business Innovations
Top 5 Main Rankings & ValueField Rankings: Two Awards Announced
Top 100 Innovative Medical Devices, Top 100 Innovative Biopharmaceuticals, Top 100 Innovative Medical Services, Top 100 Innovative Digital Health, Top 100 Innovative Overseas Healthcare; Release of the Weilan Awards and Pengcheng Awards
Gathering the Core Forces of Future Healthcare: Over 1,000 Unicorns and High-Potential Innovative Enterprises Explore Paths to Innovative Development
1+10 Industry Research Reports Released
Analysis Report on the Growth of the Top 100 Future Healthcare Companies: Defining the Growth of Core Forces in Future Healthcare
Ten Industry Research Series Reports Launched: In-Depth Insights into Niche Sectors, Exploring Development Opportunities and Innovative Cases
10+ Enterprises and Institutions Co-Creating an Industrial Innovation Ecosystem
The Future Healthcare Top 100 Conference has established in-depth collaborations with Sequoia China, Hillhouse HCare, Legend Capital, GTJA Capital, Yuanyi Capital, Shijing Medical, Yibai Technology, Qingyun Technology, Taozi Health, Jian Shi Ju, the Embassy of Canada in China, the UK Department for International Trade, the Flanders Investment & Trade Office of the Consulate General of Belgium in Shanghai, and the New* Scientific Research Enterprise Cooperation Center, to jointly foster an innovative ecosystem for the healthcare industry.
4 Countries, 20+ Innovative Project Roadshows
The Future Healthcare Top 100 Conference will collaborate with more than 20 innovative projects from Canada, the United Kingdom, Belgium, and Singapore to host global roadshows for healthcare innovation projects. By facilitating exchanges and interactions between healthcare companies and leading investment institutions, it aims to enrich the international healthcare venture capital ecosystem.
1. Focus on global challenges and future healthcare trends, the innovation strategies of Chinese innovative enterprises, and their overseas market expansion;
2、Tianzi Jiang, Director of the Brain Network Group Research Center at the Institute of Automation, Chinese Academy of Sciences; Foreign Member of Academia Europaea; Fellow of IEEE/IAPR/AIMBE，Academician of the Chinese Academy of Sciences, Chair Professor at the School of Mathematical Sciences, Peking University, and Director of the Beijing Institute for Big Data Research, E WeinanConfirmed attendance for the speech;
3. Deans and professors from prestigious institutions such as the Chinese Academy of Sciences, Peking University, Tsinghua University, Zhejiang University, and Westlake University delivered speeches, sharing insights on cutting-edge technological trends in China;
4. Top investors jointly explore the growth paths of world-class innovative enterprises and future hotspots in healthcare investment;
5. FDA Experts’ Roundtable: Sharing China’s Experience in International New Drug R&D Practices and Exploring Global Expansion Strategies;
6. Tell the innovation stories of leading enterprises centered on “in China for global.”
Section 1: | Global Challenges and the Future of Healthcare |
09:00-09:10 | Address |
Li Datao | Founder of Danhuang Technology | |
09:10-09:20 | The Five Major Challenges Currently Facing Global Public Health |
Xu Fujie | Deputy Director, Bill & Melinda Gates Foundation Beijing Representative Office(Head of Health Innovation and Collaboration) | |
09:20-09:40 | Digital Intelligence-Empowered Public Health Research |
Wu Xifeng | Dean of the School of Public Health, Zhejiang University; Vice President of the Second Affiliated Hospital, Zhejiang University School of Medicine | |
Section 2: | Soil for Innovation |
09:40-10:10 | Roundtable Discussion: International Practices in New Drug Development and Chinese Experience |
Host: Du Tao |Chairman of the FDA Experts Society, Former Senior Review Officer at the FDA, Chairman of Eglin Pharmaceuticals | |
He Ruyi | FormerChief Scientist at CDE, Chief Scientist at SDIC, and CMO of RemeGen | |
Li Ning | FormerFDA Review Division Director and Branch Chief, CEO of Junshi Biosciences | |
10:20-10:40 | The Infinite Possibilities Brought by AI + Biological Computing |
E Weinan | Academician of the Chinese Academy of Sciences, Chair Professor at the School of Mathematical Sciences, Peking University, and Director of the Beijing Institute of Big Data Research | |
10:40-11:00 | AI + Brain Health: Achievements and Future from Diagnosis to Treatment |
Tianzi Jiang | Director of the Brain Network Group Research Center, Institute of Automation, Chinese Academy of Sciences; Foreign Member of Academia EuropaeaIEEE/IAPR/AIMBE Fellow | |
11:00-11:20 | New Advances in the Translation of AI+Biopharma Achievements |
Xu Tian | Chair Professor of Genetics and Vice President, Westlake University | |
11:20-11:40 | China's Synthetic Biology Industry in a Global Context |
Chen Guoqiang | Professor at Tsinghua University, Director of the Center for Synthetic and Systems Biology | |
14:00-14:50 | Roundtable Discussion: Investing in the Future of Healthcare—How to Support the Emergence of World-Class Innovative Enterprises? |
Moderator: Sun Qi | Founding Managing Partner, Daotong Investment | |
Hong Tan | Managing Director, Legend Capital | |
Hu Xubo | Managing Partner, Qiming Venture Partners | |
Yang Yunxia | Partner at Sequoia China | |
Zhiyun Yu | Partner at Matrix Partners China | |
Zhang Yi | Managing Partner, Early-Stage Fund, Huagai Capital | |
Section Three: | In China for global |
14:50-15:10 | Full-Lifecycle, Integrated Drug R&D Solutions |
Wu Hao | Co-President, Tigermed | |
15:10-15:30 | Innovation and Globalization of Multi-Target Biologics |
Wang Zhuozhi | Vice President, New Drug R&D Services Department, WuXi Biologics | |
15:30-16:00 | Dialogue: Digitalization Leads Medical Technology, Globalization Wins the International Market |
Li Ning | Vice President of BGI Group, Executive President of the International Development Center of BGI Group | |
16:00-16:20 | The Unwavering Spirit of Original Innovation: Leading the Surgical Robotics Industry into a Golden Age |
He Chao | Minimally Invasive® Executive Director and President of Robotics | |
16:20-16:40 | Innovative Quality and Affordability for China , Serving Global Doctors and Patients |
Jiang Wei | Chief Strategy Officer, BD Greater China | |
16:40-17:00 | Inspired by Human Elements, Advancing Cell Therapy |
Wu Shu | Vice President, Legendary Biotech Product Development Platform | |
17:00-17:20 | Dialogue: The Innovative Path of Chinese Pharmaceutical Companies Expanding into Southeast Asia |
Qi Fei | Executive Director, Legend Capital Nathan Tirtana｜Etana CEO |
1. 16 leading companies delivered presentations, sharing industry trends and corporate strategic plans;
2. Comprehensive Sector Coverage: Leading listed companies in innovative drugs, IVD, cardiovascular devices, and healthcare services, exploring the development trajectory of China’s innovative forces and the forefront of medical technology concepts.
Time | Proposed Agenda Topics |
09:00-09:20 | Strategic Transformation of China Biopharmaceutical |
Xie Xin | Executive Director and Senior Vice President, China Biopharmaceutical | |
09:20-09:40 | Unlock the Multiplier Effect of the Fosun Ecosystem to Build a One-Stop Health Ecosystem |
Li Shengli | Executive President, Fosun PharmaCGO, CEO of Fosun Health | |
09:40-10:00 | Empowering Source Innovation to Build China’s Biopharmaceutical Innovation Ecosystem |
Liu Jian | BeiGene Bio-Island Innovation CenterCEO, Chairman of the Board of a Biopharmaceutical Company | |
10:00-10:20 | Discussing the Challenges and Opportunities in Cell and Gene Therapy |
Li Hong | Vice President, Global R&D Center, GenScript Biotech | |
10:20-10:40 | Development and Innovation in the ICL Industry |
Shen Ziyu | Senior Vice President, KingMed Diagnostics | |
10:40-11:00 | Domestic Medical Device Companies Riding the Wind and Waves to Go Global |
Yu Suhua | General Manager of the Cardiovascular and Cerebrovascular Business Unit at Blue Sail Medical, Blue Sail BiosensorsCEO | |
11:00-11:20 | Peijia Medical: Innovation and Internationalization Outlook |
Zhang Yi | Founder of Peijia Medical,CEO | |
11:20-11:40 | "5G Technology" for Biologics Platforms: Driving Innovation in the Pharmaceutical Industry |
Wang Jinsong | Founder, Chairman, and CEO of Harbour BioMed | |
Lunch Break | |
14:00-14:20 | Chinese Innovative Medical Services Toward Common Prosperity |
Jiang Xiaodong | Managing Partner, Changling Capital | |
14:20-14:40 | Digital-Driven Leadership in the High-Quality Development of Next-Generation Smart Hospitals |
Zhang Lizhong | Chairman of SinoCare Medical Information Technology Co., Ltd. | |
14:40-15:00 | Dual Circulation in China and Globally, Committed to Serving Global Health |
Zhang Guohua |Chairman and President of Nantong Lianya Pharmaceutical Co., Ltd. | |
15:00-15:20 | Cultivating a National Mindset for Health, Firmly Advancing Upstream |
Li Tiantian | Chairman of DXY | |
15:20-15:40 | The Next Key Point in Internet Healthcare |
Wang Hang | Founder of Haodf.com andCEO | |
15:40-16:00 | Digital Healthcare Technology Innovation: Providing Affordable Health Coverage for the Public |
Qi Lei | CFO of Magxin Health | |
16:00-16:20 | Exploration of Cancer Early Screening Adapted to China's National Conditions |
Zhang Jiangli｜Co-founder and CEO of Kunyuan Bio | |
16:20-16:40 | Building China's Leading Full-Cycle Oncology Healthcare Group |
Qiu Zejun | Co-founder and Chairman of the Supervisory Board, Baize Medical | |
1. The Future Healthcare Top 100 Conference, in collaboration with Hillhouse HCare, will launch the “Nucleic Acid Drug Innovation Development Forum,” bringing together domestic industry stakeholders across various application scenarios to comprehensively cover the development of the nucleic acid drug sector;
2、Yang Zhenjun, Professor at Peking University, Doctoral Supervisor, and Deputy Director of the Department of Medicinal ChemistryConfirmed attendance to deliver a speech, sharing insights on research into nucleic acid-based therapeutics for disease treatment.
Time | Proposed Agenda Topics |
Section I | Forward-Looking Vision |
09:00-09:20 | Study on In Vivo Delivery and Disease Treatment of Novel Lipid-Encapsulated Nucleic Acid Drug Conjugates |
Yang Zhenjun | Professor at Peking University, Doctoral Supervisor, Deputy Director of the Department of Medicinal Chemistry | |
Section II | Track Temperature |
09:20-09:40 | Targeted Delivery- The Backbone of mRNA Drug Development |
Hu Rongkuan | Xingrui PharmaceuticalsCEO | |
09:40-10:00 | RNAi: An Emerging Therapeutic Class |
Wang Weimin | CEO of Shengyin Biologics | |
10:00-10:20 | RNAa-A Unique Drug Platform for Targeted Activation of Therapeutic Genes |
Li Longcheng | Chairman of Zhongmei Ruikang andCEO | |
Section 3 | Exploring the Future |
10:20-11:00 | Roundtable Discussion: Opportunities and Challenges in the Development of Nucleic Acid Therapeutics |
Moderator: Chang Nannan | Executive Director, Hillhouse Ventures | |
Hu Rongkuan | Starry PharmaCEO | |
Wang Weimin | CEO of Shengyin Bio | |
Tang Qiusong | Head of Roche China Accelerator | |
Li Jie | Senior Vice President, Linglu Pharma |
1. The Future Healthcare 100 Conference will join forces with Sequoia China to co-host the Forum on Innovative Development of the Brain Science Industry, jointly decoding the innovation secrets of life sciences’ “final frontier”;
2. Connect resources from the Chinese Academy of Sciences, academic experts, partners of top-tier investment institutions, and innovative enterprises to drive the convergence of industry, academia, research, and investment, co-creating a medical science and technology innovation ecosystem.
Time | Proposed Agenda Topics |
Section 1 | Expedition into No-Man's Land |
09:00-09:20 | Brain-Inspired Intelligence and Brain-Computer Interfaces |
Li Chengyu | Director, Major Projects and Technology Transfer Office, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences | |
09:20-09:40 | Flexible Brain-Computer Interface Technology |
Fang Ying | Researcher, National Center for Nanoscience and Technology | |
09:40-10:00 | Neuropixels: Visualising the Rhythms of the Whole Brain |
Barun Dutta | Chief Scientist, IMEC-STS | |
Section 2 | Anchoring the Course |
10:00-10:20 | Forging a Strong Link Between Cutting-Edge Technologies and Industrialization |
Yang Yunxia | Partner, Sequoia China | |
10:20-10:40 | Brain-Computer Interface Deep Brain Stimulation |
Ning Yihua | Founder, Chairman, and General Manager of Jingyu Medical | |
10:40-11:00 | Brain-Computer Interface Technology and Industrial Translation |
Huang Xiaoshan | General Manager, Bonree Medical | |
11:00-11:20 | NeuroscienceAI: From Diagnosis to Treatment or from Treatment to Diagnosis? |
Qin Lan | Founder and Chairman of U-Brain | |
11:20-11:40 | New Perspectives on the Future of Brain Science Research, Investment, and Industrialization: Insights from SEEG Technology |
Yang Huan | Founder of Nuore Medical &CEO | |
Section III | Blue Ocean Voyage |
11:40-12:30 | Roundtable Discussion: Scientific Research- Investment - New Reflections on the Future Form of Industrialization |
Moderator: Chen Xuanze | Vice President, Sequoia China | |
Qin Lan | Founder and Chairman of U-Brain | |
Yiran Lü | Aike MedicalCEO | |
Song Donglei | Founder of Donglei Brain Hospital | |
Yang Huan | Founder of Nuoer Medical&CEO |
1. Jointly Invited by the Future Healthcare Top 100 ConferenceGlobal Health Industry Innovation Center, Peking University Medical Science Innovation Center, Zhejiang University Health Industry Innovation Research Center, Sichuan Western Pharmaceutical Technology Transfer Center, National Technology Innovation Center (Yangtze River Delta) – Biopharmaceutical Division, BlueRun Ventures, CDH Investments VGC, Yansheng Capital, Sinovation Ventures, VCBeatAs a forum support organization, and participating in the roundtable discussion of this forum;
2. The Largest Academic Medical Group in the United StatesPeng Shijie, Senior Vice President of International Affairs and Managing Director for China at UPMCInternational dialogues will be held at the Forum on the Translation of Scientific and Technological Achievements to share experiences in medical innovation from overseas research institutions and universities.
Time | Proposed Agenda Topics |
14:00-14:05 | In the Age of Medical Exploration, What Can We Do for Healthcare Innovation? |
Li Datao | Founder of VCBeat | |
14:05-14:10 | Address |
Xiao Yuan | Deputy Director of Peking University Health Science Center, Chairman of the Operating Council of PKU Medical Science and Innovation Center | |
14:10-14:50 | Roundtable Discussion: Practical Models and Trends in the Transfer and Commercialization of Research Outcomes from Scientific Institutions |
Moderator: Wang Jingjing | Executive Director, Global Health Industry Innovation Center | |
Xiao Yuan | Deputy Director of Peking University Health Science Center, Chairman of the Operational Council of PKU Medical Sci-Tech Innovation Center | |
Xing Yiqun | Director, Center for Innovation Research in Health Industries, Zhejiang University | |
Lei Juan | Director, Sichuan West Pharmaceutical Technology Transfer Center | |
Wen Tao | Deputy Director, Biopharmaceutical Division, National Technology Innovation Center of the Yangtze River Delta | |
14:50-15:05 | Sharing of Medical Innovation Experiences from Overseas Research Institutions and Universities |
Jeffrey Bernstein (Peng Shijie) |Senior Vice President, UPMC International; Managing Director, China Region | |
15:05-15:20 | TBD |
Kong Yawei | Managing Director, Asia Pacific, Cedars-Sinai International; Chief Medical Officer, International | |
15:20-16:00 | Roundtable Discussion: How Capital Empowers Innovative Research to Accelerate Its Growth into Industrial Applications |
Moderator: He Sidu | Managing Director, Danshi Capital | |
Cao Wei | Partner at BlueRun Ventures | |
Gao Jieliang | Senior Partner, Innovation and Growth Investment, CDH Investments | |
Li Kechun | Partner at Yuansheng Venture Capital | |
Ren Bobing | Executive Director at Sinovation Ventures and General Manager of the Frontier Technology Fund | |
16:00-18:20 | Project Pitch |
1. The Future Healthcare 100 Conference, in collaboration with Legend Capital, will jointly host the “Cell and Gene Therapy Development Forum,” focusing on the most cutting-edge technologies in cell therapy and gene editing;
2. VCBeat Institute Releases Its First Industry Report, “Gene Therapy: Curing at the Root, the Future Is Here,” Providing a Detailed Analysis of the Billion-Dollar Blue Ocean in the Gene Therapy Industry;
3. Liang Desheng, Deputy Director of the State Key Laboratory of Medical Genetics at Central South University, has confirmed his attendance to deliver a speech, sharing insights on research into using cell and gene therapy (CGT) to combat solid tumors.
Time | Proposed Agenda Topics |
14:00-14:20 | Report Release: "Gene Therapy——Curing from the Root, the Future is Here》 |
Wan Yuxi | Senior Researcher, VCBeat | |
14:20-14:40 | Marginal Expansion of Cell Therapy,iPSC Technology Unveils a New Chapter in Cell Therapy/Regenerative Medicine |
Yu Junying | Co-founder of Zhongsheng Suyuan | |
14:40-15:00 | Applications of Gene Therapy in Neurological Disorders |
Wu Zhenhua | CEO and Co-founder of Jiayin Biologics | |
15:00-15:20 | Gene Editing |
Wang Yongzhong | Founder of RuiZheng Gene | |
15:20-15:40 | Genetically Modified Stem Cell Therapy: Targeting Solid Tumors |
Liang Desheng | Deputy Director of the State Key Laboratory of Medical Genetics, Central South University | |
15:40-16:00 | Chemically Derived Allogeneic Cell Therapy: A New Strategy for Treating Parkinson’s Disease |
Wei Jun | Founder of Ruijian Medicine,CEO | |
16:00-16:20 | Preclinical Evaluation of Products in the CGT Field |
Wang Quanjun | Deputy Director of the Suzhou Institute for Drug Research, Chinese Academy of Sciences | |
16:20-17:10 | Roundtable Discussion:Secrets to the Clinical Translation of CGT Products |
Moderator: Wang Haotian | Vice President, Investments at Legend Capital | |
Wang Fenghua | Langxin BioCEO, Co-founder | |
Wang Quanjun | Deputy Director of the Suzhou Institute for Drug Research, Chinese Academy of Sciences | |
Lu Xin'an | Xiji BiotechCEO | |
Wei Jun | Founder of Ruijian Pharma,CEO |
1. As an ecosystem partner of the Future Healthcare 100 Conference, MedBai Technology participated in the “Pharmaceutical Company Digital Marketing Forum,”Focusing on the Marketing Development of Innovative Drug Companies under Digital Transformation;
2. VCBeat Research Institute Releases Its First Industry Report: "Digital Intelligence-Driven Marketing as the Ultimate Goal of Transformation—Report on the Digital Pharmaceutical Marketing Industry."
Digital Intelligence Ecosystem: Digital Marketing in the Pharmaceutical Industry5.0 High-Level Forum and2022 Yibai Technology 100.p MarTech Product Launch | |
Time | Agenda |
09:00-09:10 | Yibai Technology Address |
Qu Tan | Co-founder of YiBai Technology COO | |
09:10-09:30 | Digital Intelligence-Driven Marketing as the Ultimate Goal of Transformation——Report on the Digital Marketing Industry in Pharmaceuticals |
Fang Fen | Senior Researcher at VCBeat | |
09:30-09:50 | Marketing Mindset in the Digital Era |
Peng Yuanfeng | Head of Omnichannel and Market Access Training, AstraZeneca | |
09:50-10:10 | Big Data Insights into Pharmaceutical Marketing |
Lin Yanjun | Chief Strategy Officer, Yibai Technology | |
10:10-10:30 | Marketing Innovation in the Transition from Traditional to Innovative Pharmaceutical Companies |
Liu Yong | Vice President of the Marketing Center, Haisco Pharmaceutical Group; Medical Affairs&Head of Marketing Department | |
10:30-10:50 | How Digitalization Helps Pharmaceutical Companies Break Through in Marketing Under the New Situation |
Feng Rui | Concurrent Director of the Medical Affairs Department, Sichuan Otsuka, and the Health & Wellness Business Planning Department | |
10:50-11:10 | Prescription Outflow and Out-of-Hospital Sales Practices in the Era of Digital Transformation |
Wang Hui | Autoimmune Market Director, Simcere Pharmaceutical | |
11:10-11:30 | Ceremony Launch:Yibai Technology 100.pMarTech New Product Launch “Internet Hospital” & “100.MIX Cloud Director” |
11:30-11:50 | New Era of Digital Intelligence· YiBai Launches New Products: "Internet Hospital" & "100.MIX Cloud Director" |
Qu Tan | Co-founder of Yibai Technology COO | |
11:50-12:30 | Roundtable Discussion:Digital Intelligence Ecosystem · Pharmaceutical Digital Marketing 5.0 Drives Business Breakthrough |
Host: Lin Yanjun | Chief Strategy Officer of Yibai Technology | |
Peng Yuanfeng | Head of Omnichannel and Market Access Training, AstraZeneca | |
Liu Yong | Vice President of the Marketing Center, Hansoh Pharmaceutical Group; Medical Affairs&Head of Marketing Department | |
Wang Hui | Autoimmune Marketing Director, Simcere Pharmaceutical | |
Feng Rui | Concurrent Director, Medical Affairs Department, Sichuan Otsuka Pharmaceutical Co., Ltd. and Health Business Planning Department | |
Wang Zheng | General Manager, Respiratory Therapeutics Division, Hanhui Pharmaceuticals | |
Yang Bin | Vice General Manager, Pas Dualin Biopharmaceutical Co., Ltd. | |
1. The Future Healthcare 100 Conference and Shijing Medical will jointly host the "Ophthalmology Industry Innovation Forum," focusing on three key areas—ophthalmic diagnosis and treatment, optometry, and visual science—to explore innovative trends in ophthalmology and analyze investment value opportunities within the industry;
2、Wang, Chief Physician and Professor at Peking University People's HospitalLejinConfirmed attendance to deliver a speech, sharing practices and insights from a clinical perspective on the integration of digital therapeutics with ophthalmology in clinical applications;
3. VCBeat’s industry report debuts with “A Trillion-Yuan Market, a Golden Track, Innovation as the Key to Victory—2022 Ophthalmology Industry Research.”
Time | Topic Direction |
09:00-09:20 | Practice of Digital Therapeutics in Ophthalmic Clinical Applications |
Wang Lejin | Chief Physician, Professor, Peking University People's Hospital | |
09:20-09:40 | A Trillion-Yuan Market, A Golden Track, Winning Through Innovation |
Wang Shiyu | Senior Researcher, VCBeat | |
09:40-10:00 | Ophthalmology Investment from a VC Perspective |
Liang Yucheng | Head of Digital Therapeutics, Danlu Capital | |
10:00-10:20 | How Digital Therapeutics Empower Ophthalmic Diagnosis and Treatment |
Zhou Mosheng | Founder and Chairman, Shijing Medical | |
10:20-10:40 | OphthalmologyAI Enters the Era of Multi-Disease Applications |
Sun Yuhui | Founder of Zhiyuan Huitu,CEO | |
10:40-11:00 | Development Strategies and Applications of Innovative Ophthalmic Therapies Across the Full Life Cycle |
Dr. Haidi Hu | Founder and CEO of Aurigene Biologics | |
11:00-11:20 | Capital Influx, Heated Competition: How to Accelerate the Commercialization of Ophthalmic Products |
Tian Bingshi | General Manager, Business Channel Management Division, Huatang Dachang | |
11:20-11:40 | Value Upgrades for Private Hospitals Driven by Talent Development and Technological Advancement |
Zhang Haozhi | Vice President, Huaxia Eye Hospital Group | |
11:40-12:30 | Roundtable Discussion: With a Vast Population of Myopia Patients, How Can We Build a Scientific System for Myopia Prevention and Control? |
Moderator: Liang Yucheng | Head of Digital Therapeutics at Danlu Capital | |
Zhou Mosheng | Founder and Chairman of Shijing Medical | |
Wang Lejin | Chief Physician and Professor, Peking University People's Hospital | |
Ran Maoyue | Vice President, MedSci | |
Dr. Haidi Hu | Founder and CEO of Auria Biosciences |
1. Provide GPs with opportunities for in-depth, face-to-face exchanges with global LPs; 20+ top-tier investment guests have confirmed their attendance, gathering core industry forces to jointly drive transformation and innovation in the healthcare sector;
2. More focused topics, jointly exploring five core relationships: LPs and GPs, top-tier firms and small-to-medium-sized firms, investment institutions and innovative enterprises, government guidance funds and other fund-of-funds, and listed companies and the capital market.
Note: The ¥9.9 special offer ticket does not include access to this summit.
Time | Topic Direction |
Section 1: | The Path to Transformation |
14:00-14:20 | Responsibilities and Value Behind the Hard-Core Driving Force of the Mega Health Fund of Funds |
Wang Ying | Chairman of Chang Development Co., Ltd. and Chairman of Life Science Park Co., Ltd. | |
14:20-14:40 | Connecting for Win-Win Outcomes, Building aLong-Term Partnership with General Practitioners |
Hu Huanrui | Partner at Yimei Investment | |
14:40-15:00 | Angel Investment Empowers Biopharmaceuticals, Facilitating Industrial Upgrading and Development (Proposed) |
Liu Yexing | Executive Director, Shenzhen Angel Fund of Funds | |
15:00-15:20 | How Hard-Tech Investors Are Positioning Themselves in the Healthcare Sector Amid a Capital Winter |
Song Bo | Vice President of Investment, Huakong Fund | |
15:20-15:40 | InnovationThe Changes and Constants in Healthcare Investment in the 2.0 Era |
Zheng Yufen | Founder and Chairman, Yueyin Medical Fund | |
15:40-16:00 | Learning from and Innovating—Uncovering Value Depressions in China’s Intelligent Healthcare Industry |
Tian Min | Partner, Yuanjing Capital | |
Section II: | Singularity Dialogue |
16:00-16:40 | Roundtable Discussion: Decoding:“The Battle to Safeguard Investments Behind the ‘Healthy China’ Mission” |
Moderator: Xu Qian | Partner and Beijing General Manager, Danlu Capital | |
Zhang Dafeng | Founder and General Manager of Daoyuan Capital | |
Zhong Xiaopeng | Deputy General Manager, Chongqing Industrial Guidance Fund | |
Chen Guojun | General Manager, Biopharmaceutical Investment, Sichuan Venture Capital | |
Jiang Bowen | Executive Director and General Manager, Sichuan Development Hongke Fund | |
Miao Yu | Managing Director, Jinpu Health Fund | |
16:40-17:20 | Roundtable Discussion:“Healthcare + Hard Tech”: Where Lies the Paradigm of Disruptive Innovation in Life Sciences? |
Moderator: Song Bo | Vice President of Investment, Huakong Fund | |
Cai Yujia | Founder and Chairman, Bendao Gene | |
Cui Yuan | Founding Partner, Xianfeng Qiyun | |
Fang Yu | Founding Partner, Bencao Capital | |
Tao Feng | Founding Partner, Boyuan Capital | |
17:20-18:00 | Roundtable Discussion:Slowing IPOs and Valuation Corrections: Opportunities and Pathways for Exits in Healthcare Investments |
Host: Xu Huaze | Managing Partner, Yikai Fund | |
Liu Dawei | President and Founding Partner of Shanghai Biopharmaceutical Fund | |
Liu Dan | Senior Partner, CDH Investments | |
Yi Hongxiang | Partner, Shenzhen Capital Group’s Hongtu Healthcare Industry Fund | |
Zhang Song | Founding Partner, Qingsong Capital |
1. The Future Healthcare Top 100 Conference, in collaboration with Qingyun Technology, will jointly create the “Omni-channel Digital Marketing Innovation Forum”;
2. Leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Takeda, Novartis, and AstraZeneca jointly explored marketing breakthroughs in primary care markets amid intense competition.
Time | Proposed Agenda Topics |
14:00-14:10 | Chairman's Opening Remarks |
John Xu | Former Head of Roche BU | |
14:10-14:40 | Challenges and Opportunities in the New Landscape |
Li Yanshu | PwC Consulting Partner | |
14:40-15:10 | Building Data-Driven Omnichannel Marketing Capabilities Through Practice |
Yan Guowei | CEO of Qingyun Technology | |
15:10-15:40 | Promotional Practices of Virtual Representatives in the Primary Healthcare Market |
Shi Guangfan | Head of BMS Digital Marketing Team | |
15:40-16:10 | Virtual Representatives Empower New Product Launches |
Hu Qinxin | Head of Digital Innovation, Takeda | |
16:10-17:00 | Roundtable Discussion: How Primary Care Markets Can Break Through with Marketing in an Era of Hypercompetition |
| Host: Zhang Rui | Digital Transformation Expert | |
Gao Lei | Senior Channel Director, Everest Medicines | |
Feng Chun | Deputy Director, Marketing Department, Johnson & Johnson | |
Tang Xiaojing | Head of CSL Marketing Department | |
Yan Guowei | CEO of Qingyun Technology |
1. The Future Healthcare Top 100 Conference, in collaboration with Taozi Health and Yuanyi Capital, will jointly host the “Digital Therapeutics Innovation Practice Forum,” focusing on topics such as the new landscape and emerging opportunities in digital therapeutics to explore further possibilities for future innovation;
2. VCBeat Institute has released its highly anticipated special report on digital therapeutics products, titled “The Pivotal Moment for Digital Therapeutics in 2022: Three Key Questions and Reflections on Digital Therapeutics”;
3. VCBeat Senior Researcher, Global ConnectionBai Yan, Director of the Strategic Investment Department at Weimai and Co-Chair of the DTA Asia Research Center,DTA chief policy officer Megan coder，Exploring New Opportunities for International Collaboration.
Time | Proposed Agenda Topics |
Section 1: | Exploration and Practice |
09:00-09:20 | 2022: A Pivotal Moment for Digital Therapeutics — Three Key Questions and Reflections on Digital Therapeutics |
Jiang Tianjiao | Dean of VCBeat | |
09:20-09:40 | Closed-Source Digital Intervention Technology |
Zhang Jing | Senmei MedicalCEO | |
09:40-10:00 | Global Digital Therapeutics Innovation Landscape from the Perspective of Amazon Web Services |
Li Jian | Chief Business Director, Greater China, Amazon Web Services (AWS) for the Healthcare and Life Sciences Industry | |
10:00-10:20 | The Transformation of Digital Precision Management in Oncology |
Chen Kaishen | Founder andCEO | |
10:20-10:40 | Exploring the Demand for Traditional Chinese Medicine in Digital Therapeutics (TBD) |
Hou Liping | President of Taiyuan Hou Liping Traditional Chinese Medicine Hospital for Rheumatic and Bone Diseases | |
10:40-11:00 | Empowering the Digital and Intelligent Transformation of Musculoskeletal Rehabilitation——Application of Smart Sensors in Digital Therapeutics |
Zhou Kaibo | Fudong MedicalCTO | |
11:00-11:20 | In the Era of Rapid Digital Penetration, How Can Pharmaceutical Companies Achieve"Omni-channel Marketing"? |
Zhang Xinyan | Huimei Digital HealthCEO | |
Section 2: | Co-Creation and Collaboration |
14:00-14:20 | Digital Therapeutics: From Concept to Implementation |
Yang Ruirong | Partner at Yuan Yi Capital | |
14:20-14:40 | From Efficient Construction to Operational Empowerment,Case Studies of Dolphin Digital Healthcare Industrial Park |
Chen Jingbo | Vice President, Dolphin Digital Medical Industrial Park | |
15:00-15:20 | Dual-Core Drive: Sharing the Path to Efficient Construction of Digital Therapeutics |
Mao Chaolan | Executive Director, Seagull Digital Medical Device Industrial Park | |
15:20-16:00 | Global Connection |
Megan coder｜DTA chief policy officer | |
Bai Yan | Director, Strategic Investment Department, WeimaiCo-Chair of the DTA Asia Research Center | |
Chen Peng | Senior Researcher at VCBeat Eggshell Institute, Senior Editor at VCBeat | |
16:00-16:40 | Roundtable Discussion: How Digital Therapeutics Can Effectively Bridge the Healthcare Chain and Deeply Empower Upstream and Downstream Industries |
Host: Bi Yuanfeng | Co-founder of VCBeat,COO | |
Xia Wenrong | Innovation Director, Sanofi Digital Division | |
Wu Hao | Taozi Health CEO | |
Wang Li | Founding Partner, Heda Capital | |
Zhang Jing | Senmei MedicalCEO |
1、Future Healthcare100Qiangda ClubLianjun CapitalJointBuild“Life Science Tools Forum”，Invite Sino Biological、Listed Companies Such as NanoMicro TechCEODiscussing ChinaBiopharmaceuticalsExploration and Outlook;
2. Legend Capital proudly presents two high-profile panel discussions, focusing on hot topics such as the localization and internationalization of biopharmaceutical technologies, as well as the development of domestic life science tool brands;
3、Peter Peumans, Senior Fellow and CTO of Life Sciences at imecConfirmed attendance for the speech.
Time | Topic Direction |
09:00-09:20 | The Development Journey of China’s Biopharmaceutical Process Solutions Industry |
Wang Feng | Co-founder of PureBiologics,CEO | |
09:20-09:40 | How Can Domestic Consumables and Equipment Improve from the User’s Perspective? |
Li Haoqiang | Co-founder and Chairman, Haoyang Biotech | |
09:40-10:00 | The Path to Domesticating High-End Cell Culture Media for Biopharmaceuticals |
Wang Yantao | Chairman of Maibang Bio,CEO | |
10:00-10:40 | Roundtable Discussion: Localization and Internationalization of Single-Use Technologies in Biopharmaceuticals |
Moderator: Yang Shujun | Investment Director, Legend Capital | |
Jiang Biwang | Chairman of Nanomicro Tech | |
Ding Jianling | Lepu Biopharma CSO | |
Cao Liang | iVenture CEO | |
Wang Yantao | Chairman of Maibang Bio,CEO | |
10:40-11:00 | The Journey and Prospects of Domestic Life Science Reagent Enterprises in China |
Zhang Jie | General Manager, Sino Biological | |
11:00-11:20 | Exploiting deep tech for health |
Peter Peumans | CTO of Life Sciences, imec | |
11:20-12:00 | Roundtable Discussion: The Development Path of Domestic Life Science Tool Brands |
Moderator: Liu Haitao | Investment Director, Legend Capital | |
Zhang Jie | General Manager of Sino Biological | |
Huang Weihua | Founder of Yeasen Biotechnology | |
Cheng Peng | Founder of Caike Biotech | |
Zhang Han | Founder of Hanchen Guangyi |
1、ITBTCross-Boundary Integration，How Will the R&D Model and Market Landscape of Future Biopharmaceuticals Change?？ITBTForum from the track temperature、Two Pillars of the Commercial Pathway，FocusAI+Molecular Simulation,Hot Topics Such as Computer-Aided Drug Design，Explore Frontier Discussions;
2. VCBeat and Wuyuan Capital Jointly Create a VIP Roundtable,Exploring the Commercialization Path of ITBT with Representative Enterprises.
Time | Topic Direction |
Section One: | Sector Heat |
14:00-14:20 | Build the World’s Largest ThroughputDNA Synthesis Platform: Enabling Data Storage and Accelerating Biomedical Research and Innovation |
Cedric Wu | Vice President, GenScript Innovation Center | |
14:20-14:40 | Amid the Pandemic, Intelligence and Automation Drive New Drug R&D |
Zhang Peiyu | Chief Scientific Officer, XtalPi | |
14:40-15:00 | AI + Molecular Simulation—Dynamics-Based Drug Design |
Sun Weijie | Founder of DeepModeling andCEO | |
15:00-15:20 | Computer-Aided Drug Design: The Synergy Between Algorithm Development Logic and Drug Discovery Logic |
Zheng Zheng | Chairman of Yulu Qianxing | |
Section 2: | Commercialization Process |
15:20-16:00 | Roundtable Discussion:The Commercialization Path of ITBT: Technology and the Future |
Host: Jing Xutian | Managing Director, Source Code Capital | |
Chen Hang | Co-founder and CEO of Xingkangyuan | |
Lai Caida | Co-founder of MetagenomiCEO | |
Wang Yuchong | Founder and CEO of Chenan Bio | |
Wen Shuhao | Co-founder and Chairman of XtalPi | |
Wen Wen | Founder of Huanyi Biotech,CEO |
1. VCBeat Releases Its Report “The Era of Health Insurance 3.0: Digitalization Empowers Health Insurance to Break Free from Cutthroat Competition and Achieve Renewal.” What stage of development is the health insurance industry currently in? Where is it headed in the future? What are the key characteristics of this new development phase? The forum will provide an on-site interpretation of the report’s findings and share insights into emerging trends;
2. Eight innovative companies delivered presentations, sharing future trends from the perspectives of technology empowerment and integrated development.
Time | Proposed Agenda Topics |
Section 1: | Forward-Looking Vision |
14:00-14:20 | Health Insurance 3.0 Era: Digitalization Helps Health Insurance Break Through "Involution" and Rebirth |
Huang Shun | Senior Researcher, VCBeat | |
Section II: | Technology Empowerment |
14:20-14:40 | Application of Digital Therapeutics in the Field of Chronic Diseases |
Gu Shufeng | Senior Vice President, Miao Health | |
14:40-15:00 | Data-Intelligence-Driven Healthcare"New Private Domain" Layout |
Lai Gangbin | Founder of Jingli Technology,CEO | |
15:00-15:20 | A Home Endocrine Testing and Health Management Platform for 100 Million Female Users |
Wang Qiangyu | Founder of Yisheng Jiankang andCEO | |
15:20-15:40 | Pioneer and Leader in Digital Therapeutics for Chronic Pain in China |
Luo Min | Co-founder of Tengai Health,CEO | |
15:40-16:00 | How to Build“Underwriting + Claims Settlement + Health Management” Insurance Closed-Loop Ecosystem? |
Xing Jing | Founder and CEO of Shangyong Technology | |
Section 3: | Integrated Development |
16:00-16:20 | The Practice of Deep Integration Between Full-Lifecycle Health Management and Health Insurance |
Xu Bingyu | Founder of Huamei Haolian,CEO | |
16:20-16:40 | # The Way to Break Through in Health Insurance |
Zhao Huazhong | Founder of Universal Care,CEO | |
16:40-17:00 | Technological Innovation: Optimizing the Management Model for Chronic Diseases in China |
Bai Rui | Senior R&D Director, Zhiyun Health |
1. The Future Healthcare 100 Conference and Jian Shi Ju will jointly host the “Forum on Innovative Development in Assisted Reproductive Technology,” where experts and publicly listed companies will interpret policies and industry development strategies in the field of assisted reproduction.
2. Invite chief professors from Peking University People's Hospital, the First Affiliated Hospital of Nanjing Medical University, Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, the Reproductive Medicine Center of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, and the Reproductive Medicine Center of Peking Union Medical College Hospital to attend and share topics on practical explorations in the field of assisted reproduction.
3. VCBeat’s Assisted Reproductive Technology Industry Report: Major Release of “2022 Assisted Reproductive Technology Industry Research: Policy Dividends Will Become the Driving Force Behind an 800 Billion Market”
Time | Topic Direction |
Section 1: | Policy Orientation |
09:00-09:15 | Leader's Address |
Li Yuedong | Executive Director of the China Hospital Association, Former Party Secretary of Peking University People's Hospital | |
09:15-09:20 | Launch Ceremony of the China Assisted Reproductive Technology Policy Report |
09:20-09:40 | Interpretation of the Report “Analysis of China’s Assisted Reproductive Technology Policies 2022” |
Sun Tao | Deputy Editor-in-Chief, Jian Shi Ju | |
09:40-10:00 | Reproductive Medicine and China's Population Strategy |
Jiayin Liu |Former Director of the Reproductive Medicine Center, Jiangsu Province Hospital | |
10:00-10:20 | The Importance of Assisted Reproductive Technology in the Context of Low Fertility Rates |
Kuang Yanping | Director, Department of Assisted Reproduction, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | |
10:20-10:40 | Can IVF Become Accessible to the General Public? |
Zhang Hanwang | Chief Physician, Reproductive Medicine Center, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology | |
Section II: | Exploration and Practice |
10:40-11:00 | 2022. Research on the Assisted Reproductive Technology Industry: Policy Dividends Will Become the Driving Force Behind an 800 Billion Market |
FanXiaoyu | VCBeatSenior Researcher | |
11:00-11:20 | Strategic Choices for Non-Public Assisted Reproductive Technology Institutions |
Duan Tao | Chief Scientific Officer, Jinxin Fertility | |
11:20-11:40 | Ultrasound Solutions in the Field of Reproduction |
Xiao Huiru｜Academic Manager, Clinical Academic Department of Global Ultrasound Imaging Products, Mindray Medical | |
11:40-12:00 | Exploration and Practice in Assisted Reproduction by He Fangfang Studio |
He Fangfang | Founder of the Reproductive Medicine Center at Peking Union Medical College Hospital, Founder of He Fangfang Reproductive Medicine Studio |
1. Focusing on the continuous development of China's personalized diagnosis and treatment industry from four perspectives—industry trends, technological R&D, clinical applications, and developmental discussions—to promote the innovative integration of industry, academia, research, and application across the entire process in the field of tumor screening and diagnosis;
2. First Release of Two Industry Reports: "Clinical Mass Spectrometry Report" and Cancer Early Screening Report.
Time | Proposed Agenda Topics |
09:00-09:20 | 2022 Industry Research Report on Early Cancer Screening: Commercialization Driven by Liquid Biopsy |
Lulu Cui | Senior Researcher, VCBeat | |
09:20-09:40 | Panoramic Insights: Next-Generation Pathology (NGP) Empowers Precision Diagnosis and Treatment of Cancer |
Zhang Rui | Executive Deputy General Manager, Kuoran Genomics | |
09:40-10:00 | MRD Testing and Precision Oncology |
Zhong Liangqi | Vice President of LDT Sales, TreeGene Genetics | |
10:00-10:20 | Applications and Prospects of MRD in the Era of Digital Precision Medicine |
Wang Weifeng | Senior Vice President, R&D Department, Geneseeq | |
10:20-10:40 | Micro-Tumor Drug Sensitivity Testing Technology Leads New Breakthroughs in Precision Oncology Diagnosis and Treatment |
Xia Yuchao | CIO, Cornerstone Life; Ph.D. | |
10:40-11:00 | New Directions in Precision Diagnostics Post-NGS: Seven Major Technology Platforms Accelerate the Clinical Adoption of Mass Spectrometry |
Jiao Yanli | Senior Researcher, VCBeat | |
11:00-11:50 | Roundtable Discussion: Personalized Life: Precision Oncology Opens a New Chapter in the Future of Cancer Treatment |
Moderator: Cheng Hao | Managing Director, Shengshan Capital | |
Ding Fang | CEO of Dajian Biotech | |
Zhong Liangqi | Vice President of LDT Sales, Tree Genetics | |
Wang Weifeng | Senior Vice President, R&D Department, Burning Rock Biotech | |
Zhang Rui | Executive Deputy General Manager of Kuoran Gene | |
Xia Yuchao | CIO of Geneseeq, Ph.D. |
1. The Future Healthcare Top 100 Conference, in collaboration with GTJA Capital, will jointly host the “Small Molecule Innovative Drug Development Forum.” Focusing on the latest hot topics in small molecule innovative drugs, the forum will bring together leading enterprises and investors to conduct an in-depth analysis of the prospects, directions, and bottlenecks in the development of small molecule drugs, as well as future challenges;
2. VCBeat Institute Debuts Its Industry Report, “New Industry Trends Led by Small-Molecule Degraders,” with an In-Depth On-Site Analysis of Hot Small-Molecule Segments.
Time | Proposed Agenda Topics |
Section 1: | Investors Say |
09:00-09:20 | The New Journey in the Development of Innovative Small-Molecule Drugs in China |
Teng Yuhang | Executive Partner, GTJA Investment Group | |
Section 2: | Track Temperature |
09:20-09:40 | Develop Best-in-Class Innovative Anti-Tumor Drugs |
Xu Yinglin | Chairman, Chief Executive Officer and President of Xunuo Pharmaceutical | |
09:40-10:00 | Clinical Demand-Driven Innovation in Ophthalmic Drugs |
Shen Wang | Founder, Chairman andCEO | |
10:00-10:20 | Crowded Field: How Can Small-Molecule Conjugate Drugs Stand Out? |
Ma Zhenkun | Founder andCEO | |
10:20-10:40 | How to Become a Pharmaceutical Company's“New R&D Partners”? |
Ji Xuwo | Founder of Purui Benchmark,CEO | |
Section 3: | Report Debut |
10:40-11:00 | The New Industry Trend Led by Small-Molecule Degraders |
Wang Jiaqi | Senior Researcher at VCBeat |
1、ShanghaiTech University School of Biomedical Engineering Founding Dean / United Imaging Intelligence Co-CEO Dinggang ShenConfirmed to deliver a speech, discussing technological trends and future advancements from the perspective of AI research and applications in medicine
2. What Will the Future Form of Medical AI Look Like? Innovative Companies Such as Danlu Capital, Microsoft China, Tangerine MedTech, and Deepwise Medical Will Explore the Future of Technological Transformation Through the Integration of AI in Their Respective Fields
Time | Proposed Agenda Topics |
Section 1 | Forward-Looking Vision |
09:00-09:20 | Research and Application of AI Imaging in the Future Development of Medicine |
Shen Dinggang | Founding Dean, School of Biomedical Engineering, ShanghaiTech University / Co-CEO, United Imaging Intelligence | |
Section II | Industry Exploration |
09:20-09:40 | Current Status and Development Trends of Medical AI in the Diagnosis and Treatment of Cardiac Health |
Li Guang | Algorithm Director, Keya Medical Technology Co., Ltd. | |
09:40-10:00 | Providing physicians with the ultimate in brain, eye, and hand capabilities. |
Zheng Lingxiao | Founder and CEO, Ruixin Medical | |
10:00-10:20 | Laying the Foundation for AI-Assisted Diagnosis: The Normalization of Digital Diagnostics |
Fan Yujun | Founder of Tangerine, General Manager of Suruidi Medical Technology | |
10:20-10:40 | AI-Integrated Imaging Middleware Development |
Chen Chuang | Product Manager, Kayi Smart Products Department | |
Section III | Future Perspectives |
| 10:40-11:00 | TBD |
| Wu Zhiyong | Executive Director of Hunan Meixihu New City Medical Investment Co., Ltd. | |
11:00-11:40 | Roundtable Discussion: Technology and Applications: Exploring the Future Form of Medical AI |
Moderator: Fang Wenhan | Vice President, Danlu Capital | |
Fan Yujun | Founder of Tangier, General Manager of Suruide Medical Technology | |
Zhang Qiang | Head of Microsoft’s National AI Program, Greater China | |
Qiao Xin | Co-founder and CEO of Deepwise AI |
1、Li Jian’an, International Fellow of the U.S. National Academy of Medicine and Director of the Center for Rehabilitation Medicine at the First Affiliated Hospital of Nanjing Medical UniversityConfirm Attendance for Speech，Sharing in the Era of Aging，Cutting-Edge Concepts in Rehabilitation;
2、Chen Yue, Clinical Doctor of Health Sciences from The Hong Kong Polytechnic University and Director of the Treatment Department at Chengdu Gulian Jinchen Rehabilitation HospitalA clinical perspective on the future of technology-enabled rehabilitation medicine.
Time | Proposed Agenda Topics |
Section 1 | Frontier Perspectives |
14:00-14:20 | Proactive Health and Active Aging |
Li Jian’an | International Fellow of the National Academy of Medicine | |
14:20-14:40 | Clinical Applications of Rehabilitation Medicine Empowered by Technology |
Chen Yue | Director of the Department of Therapy, Chengdu GooChain Jinchen Rehabilitation Hospital; Doctor of Clinical Health Sciences, The Hong Kong Polytechnic University | |
Section 2 | Industry Innovation |
14:40-15:00 | “New Decade of Exoskeletons”: Innovative Rehabilitation Solutions |
Wang Tian | CEO and Founder of Chengtian Technology | |
15:00-15:20 | Key Technologies for AI-Powered Rehabilitation Robots and Cloud Service Platforms |
Zhang Qian | Marketing Director, Shanghai Jinshi Robotics Technology Co., Ltd. | |
15:20-15:40 | From Hospital to Home: How Digital Technology Empowers Rehabilitation? |
Yin Ganggang | General Manager, Shanghai Siyi Intelligent Technology Co., Ltd. | |
Section 3 | Future-Oriented |
15:40-16:20 | Roundtable Discussion: New Scenarios, New Technologies, and New Trends in the Future of Rehabilitation Medicine |
Host: Kang Liangjin | Senior Investment Director, Daoyuan Capital | |
Chen Yue | Director of the Treatment Department, Chengdu Gulian Jinchen Rehabilitation Hospital; Doctor of Clinical Health Sciences, The Hong Kong Polytechnic University | |
Zhang Jiyu | COO and Co-founder, Chengtian Technology | |
Sun Xiaoyi | Founder of Shanghai Youfu Rehabilitation Medicine Outpatient Department |
1、President, Healthcare and Health Industry Branch, China Information AssociationSong XinConfirmed to Attend the Speech: Interpreting the Coordinated Development of the “Trinity” Model from a Policy Perspective；
2. How to Build Hospital Information Systems? In the Digital Era, How to Foster an Innovative Ecosystem for Smart Healthcare? A Hospital Director and Four Innovative Companies Share Insights and New Trends in Smart Hospitals.
Time | Proposed Agenda Topics |
Section 1: | Policy Orientation |
14:00-14:20 | How Policies Provide Support"Trinity" Coordinated Development |
Song Xin | President of the Medical and Health Industry Branch, China Information Association | |
14:20-14:40 | Current Status and Future Prospects of Hospital Information Technology Construction |
Xiang Peng | Deputy Secretary of the Party Committee and Executive Vice President of Jiande First People's Hospital | |
Section 2: | Digital Leadership, Smart Connectivity |
14:40-15:00 | BOE Health: IoT Hospitals Empowering Full-Course-of-Care Services |
Jiang Maorong | President of BOE Health IoT Hospital | |
15:00-15:20 | The Future of Mental Healthcare |
Xu Feng | Good MoodCOO | |
15:20-15:40 | Compliance and Current Status of Internet Healthcare Development- Digital Transformation in the Era of "Internet Plus" |
Qu Yi | Founder of Naiterui,CEO | |
15:40-16:00 | Digital Innovation- Empowering the Reconstruction of a New Smart Healthcare Ecosystem |
Yang Jiawei | Chief Market Strategy Officer, Haihu Medical Technology |
1、Tao Liang, President of Wuhan Asia Heart HospitalFeatured Speech，An Analysis of the Path to Translational Cardiovascular Research from a Clinical Perspective;
2. Covering hot sectors such as aortic valve, mitral valve, tricuspid valve, and vascular interventional surgical robots; focusing on frontier technologies in the cardiovascular industry and hot topics like medical-engineering integration and research translation;
3. VCBeat Institute Releases Major Cardiovascular Industry Report: “How to ‘Win’ the Breakout Battle in the New Landscape?”
Time | Proposed Agenda Topics |
Section 1: | Frontier Perspectives |
14:00-14:20 | From Clinical Needs to Practice: What Is the Future of Innovation in Cardiovascular Surgical Procedures? |
Tao Liang | President of Wuhan Asia Heart Hospital | |
14:20-14:40 | Med-Eng Integration and Research Translation: Challenges and Future of Cardiovascular Medical Device Commercialization |
Wang Jie | Sinomed MedicalCEO | |
15:00-15:20 | Under the New Landscape, How to “Win” the Breakout Battle? |
Qu Xinyu | Senior Researcher at VCBeat | |
Section 2: | Technological Revolution: Innovative Tracks |
15:20-15:40 | China’s Path of Innovation in Valve Interventional Therapy |
Gao Dan | Vice President of Finance and Capital Markets, Peijia Medical | |
15:40-16:00 | Chinese Wisdom, Illuminating the Global Field of Structural Heart Disease |
Lin Lin | Huihe MedicalCEO, Founder | |
16:00-16:20 | Continuously Innovate to Build an International Brand for Cardiovascular Implantable and Interventional Medical Devices with High-Quality Products |
Gong Xiaoyan | Founder of InnoLoom Medical | |
16:20-16:40 | To be determined |
Huo Yunlong | Founding Shareholder of Rainmed Medical, Professor at the School of Life Sciences and Biotechnology, Shanghai Jiao Tong University |
VCBeat, in collaboration with the Canadian Embassy in China, the UK Department for International Trade, the Flanders Investment & Trade Office of the Consulate General of Belgium in Shanghai, and the Sino-Singapore Research Enterprise Cooperation Center, jointly hosted a global roadshow for innovative healthcare projects. This initiative aimed to enrich the international healthcare venture capital ecosystem by facilitating exchanges and interactions between healthcare companies and leading investment institutions.
Time | Agenda |
Canada Special | |
08:30-08:40 | Address |
Francis Gagnon (Gao Zhengqing) | Director and Commercial Commissioner of the Quebec Government Representative Offices in Beijing and Qingdao, Counsellor at the Canadian Embassy in China | |
08:40-08:50 | Quebec Promotion |
Wang Shanshan | Senior Trade Commissioner, Quebec Government Office in Beijing | |
Wang Yuanyuan | International Foreign Direct Investment Officer, Investissement Québec | |
08:50-10:35 | Project Pitch |
Gao Lining |CAE Healthcare China Regional Manager | |
Naheed Kurji ｜ Cyclica Co-founder, Pres & CEO | |
Hu Jun Hu Jun | Neurolus AI China Regional Manager | |
Qiu Dongxiao |Precision Medtech Canada Co., Ltd. CEO | |
Morteza Ahmadi ｜Qidni CEO | |
Tianfang Wang | General Manager, Chaomu Technology | |
Liu Wenlong |Thought Tech Marketing Director | |
Belgium Special | |
10:35-10:45 | Address |
Bart Boschmans (Lin Bosen) | Consul for Flanders Business, Consulate General of Belgium in Shanghai | |
10:45-10:55 | Flemish Region, Belgium ——Gateway to European Biotechnology |
Zhang Xiaoyun | Investment Director, Flanders Investment & Trade Office, Consulate General of Belgium in Shanghai | |
10:55-12:05 | Project Pitch |
Jeremy Yang | Strategic Cooperation Manager, imec | |
Sven Agten｜Agio Capital Partner | |
Steven Powell | Etherna CEO | |
Jean-Paul Bogers｜Elmedix CEO | |
Andre Rosenthal｜Fertiga CEO | |
UK Special | |
14:00-14:15 | Address |
Gary Hunt｜British Consulate-General in Shanghai Assistant Director, Health & Life Sciences | |
14:15-15:45 | Project Roadshow |
Xu Lin | Quality Manager, Suzhou Kadimoke Medical Devices Co., Ltd. | |
Xiaomeng Li | Co-founder and Head of Clinical Research, Seroxo | |
Chen Xuesong |CEO of OXSIGHT China | |
Yang Junjun |Director of Market Development, China and Asia-Pacific, Congenica | |
George Frodsham ｜MediSieve CEO | |
Craig Dookie｜Kmira Founder/Director | |
Singapore Special | |
15:45-16:00 | Address |
Chen Quancheng | Director, New * Scientific Research Enterprise Cooperation Center | |
16:00-17:15 | Project Pitch |
Chen Minhan | Lusheng BiotechnologyCEO | |
Chen Shunxing | Co-founder of Dandelion Biotechnology | |
Xu Shuoyu | Chief Scientist, Bio-Totem | |
Li Deli | Zhongyi ZhichuangCEO | |
Wang Xiuhua | Founder of Ruizhi Haoming | |
June 14–18, 2022
20+ Themed Forums,200+ Industry Leaders Delivering Insightful Presentations,
10+ Industry Reports Released, Global Project Roadshows in 4 Countries, LPGP Summit...
Top 100 Future Healthcare Companies List and Awards Announced,Access to a Professional Network of Thousands in the Industry
Limited-Time Special: ¥9.9 – Scan the QR Code to Register